MX9604635A - Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento. - Google Patents

Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.

Info

Publication number
MX9604635A
MX9604635A MX9604635A MX9604635A MX9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A MX 9604635 A MX9604635 A MX 9604635A
Authority
MX
Mexico
Prior art keywords
growth hormone
patient
igf
serum level
below normal
Prior art date
Application number
MX9604635A
Other languages
English (en)
Inventor
Kenneth Attie
Lena M S Carlsson
Neil Gesundheit
Audrey Goddard
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22843052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9604635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX9604635A publication Critical patent/MX9604635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a métodos para incrementar el índice de crecimiento de un paciente humano que padezca el síndrome de insensibilidad parcial a la hormona del crecimiento, pero no síndrome de Laron. Uno de tales métodos comprende administrar una dosis efectiva de hormona del crecimiento, de preferencia hormona del crecimiento con una secuencia nativa, con o sin una metionina N-terminal, al paciente. El paciente se caracteriza por tener una estatura menor de aproximadamente -2 desviaciones estándar por abajo de lo normal para la edad y sexo, un nivel sérico de proteína de union a la hormona del crecimiento de alta afinidad que está cuando menos desviaciones estándar por abajo de los niveles normales, un nivel sérico de FCI-I que está por abajo de los niveles promedio normales y un nivel sérico de hormona del crecimiento que es cuando menos normal. En otro método, la misma poblacion de pacientes es tratada con una cantidad efectiva de FCI-I, administrada sola o en combinacion con una cantidad de hormona del crecimiento que sea efectiva en combinacion con el FCI-I.
MX9604635A 1994-04-07 1995-03-24 Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento. MX9604635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/224,982 US5646113A (en) 1994-04-07 1994-04-07 Treatment of partial growth hormone insensitivity syndrome
PCT/US1995/003731 WO1995027495A2 (en) 1994-04-07 1995-03-24 Treatment of partial growth hormone insensitivity syndrome

Publications (1)

Publication Number Publication Date
MX9604635A true MX9604635A (es) 1997-11-29

Family

ID=22843052

Family Applications (2)

Application Number Title Priority Date Filing Date
MX9604635A MX9604635A (es) 1994-04-07 1995-03-24 Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.
MX9701916A MX9701916A (es) 1994-04-07 1995-03-24 Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX9701916A MX9701916A (es) 1994-04-07 1995-03-24 Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.

Country Status (12)

Country Link
US (1) US5646113A (es)
EP (1) EP0754048B1 (es)
JP (2) JP3366644B2 (es)
AT (1) ATE203165T1 (es)
CA (1) CA2187274C (es)
DE (1) DE69521796T2 (es)
DK (1) DK0754048T3 (es)
ES (1) ES2160704T3 (es)
GR (1) GR3036901T3 (es)
MX (2) MX9604635A (es)
PT (1) PT754048E (es)
WO (1) WO1995027495A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) * 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
DK2274978T3 (en) * 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
JP5460958B2 (ja) * 2004-03-17 2014-04-02 アンチキャンサー インコーポレーテッド タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1866427A4 (en) * 2005-03-30 2010-09-01 Novo Nordisk As METHOD OF MANUFACTURING PEPTIDES PRODUCED IN INSECT CELL LINES
EP1871795A4 (en) * 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
WO2006130769A2 (en) * 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
US10383919B1 (en) * 2013-05-31 2019-08-20 The University of the Sciences Fragments of growth hormone binding protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy

Also Published As

Publication number Publication date
ATE203165T1 (de) 2001-08-15
DE69521796D1 (de) 2001-08-23
JP3366644B2 (ja) 2003-01-14
US5646113A (en) 1997-07-08
WO1995027495A2 (en) 1995-10-19
EP0754048B1 (en) 2001-07-18
PT754048E (pt) 2002-01-30
JP2000226334A (ja) 2000-08-15
MX9701916A (es) 1997-06-28
CA2187274A1 (en) 1995-10-19
ES2160704T3 (es) 2001-11-16
JPH09509430A (ja) 1997-09-22
DE69521796T2 (de) 2002-05-23
EP0754048A1 (en) 1997-01-22
WO1995027495A3 (en) 1995-12-28
CA2187274C (en) 2001-01-02
GR3036901T3 (en) 2002-01-31
DK0754048T3 (da) 2001-11-05

Similar Documents

Publication Publication Date Title
MX9701916A (es) Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.
SE8703625D0 (sv) New medical use
IL154797A0 (en) Vascular endothelial cell growth factor that is unaccompanied by associated native glycosylation, pharmaceutical composition containing it and use thereof in the manufacture of a medicament for treating trauma affecting the vascular endothelium
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
NO940180L (no) Anvendelse av IGF-I
ATE536186T1 (de) Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
PT914148E (pt) Tratamento do sindroma de insensibilidade parcial a hormona de crescimento
HU9202092D0 (en) An implantate composition containing biologically active protein, peptide or polypeptide
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE184489T1 (de) Behandlung fehlender milchabsonderung beim menschen
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE251640T1 (de) Neues chondrozytprotein
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
DE69113773D1 (de) Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma.
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie